228 related articles for article (PubMed ID: 33835479)
1. Cell signaling in cutaneous T-cell lymphoma microenvironment: promising targets for molecular-specific treatment.
Rendón-Serna N; Correa-Londoño LA; Velásquez-Lopera MM; Bermudez-Muñoz M
Int J Dermatol; 2021 Dec; 60(12):1462-1480. PubMed ID: 33835479
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
3. New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications.
Luna DE; Shinohara MM
Curr Hematol Malig Rep; 2023 Jun; 18(3):83-88. PubMed ID: 37017872
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
[TBL] [Abstract][Full Text] [Related]
5. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.
Durgin JS; Weiner DM; Wysocka M; Rook AH
J Am Acad Dermatol; 2021 Mar; 84(3):587-595. PubMed ID: 33352267
[TBL] [Abstract][Full Text] [Related]
6. Mapping signal transducer and activator of transcription (STAT) activity in different stages of mycosis fungoides and Sezary syndrome.
Olszewska B; Żawrocki A; Lakomy J; Karczewska J; Gleń J; Zabłotna M; Malek M; Jankau J; Lange M; Biernat W; Nowicki RJ; Sokołowska-Wojdyło M
Int J Dermatol; 2020 Sep; 59(9):1106-1112. PubMed ID: 32643174
[TBL] [Abstract][Full Text] [Related]
7. The Role of Cytokines in Cutaneous T Cell Lymphoma: A Focus on the State of the Art and Possible Therapeutic Targets.
Guglielmo A; Zengarini C; Agostinelli C; Motta G; Sabattini E; Pileri A
Cells; 2024 Mar; 13(7):. PubMed ID: 38607023
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic approaches for cutaneous T cell lymphomas.
Pavlidis A; Piperi C; Papadavid E
Expert Rev Clin Immunol; 2021 Jun; 17(6):629-641. PubMed ID: 33890833
[No Abstract] [Full Text] [Related]
9. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
10. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
[TBL] [Abstract][Full Text] [Related]
11. Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.
Nguyen CN; Iyer SP; Duvic M; Barde PJ; Nair A; Routhu KV; Huen AO
Invest New Drugs; 2023 Apr; 41(2):350-355. PubMed ID: 37004644
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional Heterogeneity and the Microbiome of Cutaneous T-Cell Lymphoma.
Licht P; Mailänder V
Cells; 2022 Jan; 11(3):. PubMed ID: 35159138
[TBL] [Abstract][Full Text] [Related]
13. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
Ramelyte E; Dummer R; Guenova E
Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
[No Abstract] [Full Text] [Related]
14. An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma.
Hu M; Scheffel J; Elieh-Ali-Komi D; Maurer M; Hawro T; Metz M
Clin Exp Med; 2023 Dec; 23(8):4177-4197. PubMed ID: 37555911
[TBL] [Abstract][Full Text] [Related]
15. Epigenetics of Cutaneous T-Cell Lymphomas.
Hara N; Sawada Y
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408897
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.
Devata S; Wilcox RA
Am J Clin Dermatol; 2016 Jun; 17(3):225-37. PubMed ID: 26923912
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
18. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways.
Pérez C; Mondéjar R; García-Díaz N; Cereceda L; León A; Montes S; Durán Vian C; Pérez Paredes MG; González-Morán A; Alegre de Miguel V; Sanz Anquela JM; Frias J; Limeres MA; González LM; Martín Dávila F; Beltrán M; Mollejo M; Méndez JR; González MA; González García J; López R; Gómez A; Izquierdo F; Ramos R; Camacho C; Rodriguez-Pinilla SM; Martínez N; Vaqué JP; Ortiz-Romero PL; Piris MA
Br J Dermatol; 2020 Jan; 182(1):147-155. PubMed ID: 31049933
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma.
Peru S; Prochazkova-Carlotti M; Cherrier F; Velazquez J; Richard E; Idrissi Y; Cappellen D; Azzi-Martin L; Pham-Ledard A; Beylot-Barry M; Merlio JP; Poglio S
J Invest Dermatol; 2022 Dec; 142(12):3243-3252.e10. PubMed ID: 35850209
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways.
Patil K; Kuttikrishnan S; Khan AQ; Ahmad F; Alam M; Buddenkotte J; Ahmad A; Steinhoff M; Uddin S
Semin Cancer Biol; 2022 Nov; 86(Pt 3):382-399. PubMed ID: 34906723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
